Promotion scale: 4 people last year → 6 people this year
One vice president promoted and five managing directors appointed
This year, Samsung biologics’ cumulative orders exceed KRW 5 trillion.
Vice President Kevin sharp, who led the order, was promoted after three years.
new representative system epis appoints 3 new executives
Samsung BioLogics promoted executive promotions based on it’s high order performance this year. A total of 6 people were promoted, which is 2 more than last year (4 people). Executive Director Kevin Sharp, who led large-scale new orders from global pharmaceutical companies, was promoted to Vice President, and public Relations Team Leader In-chan Hwang, who contributed to enhancing the brand image through active dialog with domestic and foreign press and media, was selected as a new executive.
Samsung BioLogics announced on the 29th that it has carried out regular personnel reshuffle of six executives in 2025 in accordance with performance-based personnel principles.
Managing Director Kevin Sharp, who had been serving as NJ Sales Office Head, was promoted to Vice President in this personnel change. After being appointed as a new executive in 2021,he was appointed vice president three years later. It is evaluated that Samsung BioLogics has secured large-scale orders from overseas pharmaceutical companies and established Samsung BioLogics’ presence in the global contract research and growth (CDMO) market. The new vice president, Kevin Sharp, is from GlaxoSmithKline (GSK) in the U.S. and joined Samsung BioLogics as a sales team leader in 2017. Afterwards, he served as the head of the Strategic Ops team and general manager of sales as part of the Global Sales Center.
In addition, five new executives were appointed. Managing Director Seong-cheol Yoo led the full operation of Plant 3 by streamlining the production process and schedule management and contributed to the increase in sales through stable pharmaceutical production. Managing Director Song In-seop, who improved the purchasing and outsourcing process, established an efficient supply chain management system (SCM), and led the enhancement in cost competitiveness, also became an executive. Managing Director Lee Tae-hee, who contributed to strengthening the competitiveness of the CDManaging Director Hwang In-chan was selected as a new executive in recognition of his contributions to improving the corporate image and improving brand value in the CDMO market through active internal and external communication. People Center PE Team Leader Song Young-seok (Human Resources), who led the establishment of a unique organizational culture such as Samsung BioLogics Way, was also appointed as managing director.
An official from Samsung BioLogics said, “We have boldly selected talent who have proven the potential to drive lasting growth and outstanding performance,” and added, “We will secure future competitiveness and further solidify our position as a global leading company.” Samsung BioLogics plans to carry out company-wide reorganization and personnel changes following regular executive personnel appointments.
samsung Bioepis, a subsidiary where a new CEO was appointed, also carried out executive promotions.Without promotion of existing executives, three new executives, including Managing Director Kang Dae-seong, Managing Director Gil Ji-hoon, and Managing Director Bong Gi-tae, were selected as new executives.
The following are those eligible for executive promotion at Samsung BioLogics.
[삼성바이오로직스]
◇ Promotion to Vice President (1 person)
▲Vice President Kevin Sharp
◇ Newly appointed managing director (5 people)
▲Director Seongcheol Yoo
▲Director Song In-seop
▲Director Lee Tae-hee
▲Director Hwang In-chan
▲Director Song Young-seok
[삼성바이오에피스]
◇ Newly appointed managing director (3 people)
▲Director Kang Dae-seong
▲Director Gil Ji-hoon
▲Director Bong Ki-tae
Kim Min-beom, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m sad
- 0dog